Indaptus Therapeutics is trading 8.24% down at $2.38, with the decline consistent with broader equity and biotech weakness; no fresh company-specific catalyst appeared in available search results. - October 7 market coverage cited rising oil and Treasury yields, geopolitical supply concerns, and caution ahead of Fed minutes. - Supplied sector context shows XBI down 2.50%; trading volume was not available in the supplied context or search results.